This patient’s tumor metabolism suggests an adaptive survival program, boosting glycolytic flux via PKM and PGK1 to meet energetic and biosynthetic demands, while downregulating ribosomal machinery to conserve resources, potentially in an mTOR-influenced and immune-suppressive context. The gene discussed is MTOR; the disease is neoplasm.